Business Context and Reporting Period
This filing is a Form 10-K for the fiscal year ended December 31, 2018, filed March 29, 2019. The registrant is identified in the filing as PowerVerde, Inc.; the request metadata identifies 374Water Inc. The filing describes PowerVerde as a development-stage clean-energy engineering company focused on pressure-driven expanders, organic Rankine cycle systems, and high-temperature/high-pressure applications. The company had one full-time employee and had not generated material revenue from its planned power-generation operations.
During 2018, PowerVerde began engineering work related to Duke University's supercritical water oxidation project and its proposed collaboration with 374Water. Management stated that the company was transitioning toward specialty engineering applications, including residual heat-to-power systems for municipal sanitation.
Key Financial Metrics
| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Revenue | $190,094 | $852,443 | Down 77.7% |
| Research and development expense | $630,742 | $210,624 | Up 199.5% |
| General and administrative expense | $239,352 | $210,491 | Up 13.7% |
| Operating loss | $680,000 | Operating income of $431,328 | Material deterioration |
| Net loss | $679,078 | Net income of $404,353 | Material deterioration |
| Basic and diluted loss per share | $0.02 loss | $0.01 income | Material deterioration |
| Cash flow from operations | $157,146 provided | $271,550 provided | Down 42.1% |
| Cash and cash equivalents | $8,482 | $1,336 | Up $7,146 |
| Working capital | $9,788 deficit | $168,859 positive | Deteriorated by $178,647 |
| Accumulated deficit | $12,057,798 | $11,378,720 | Increased $679,078 |
2018 revenue consisted primarily of $159,094 in final biotech licensing royalties and $31,000 from manufacturing assembly services. The filing states that the licensing agreement expired in March 2018 and that the final royalty payment was received in the second quarter. The company generated no revenue from its planned principal operations.
Operating margin was approximately negative 357.7% in 2018, compared with approximately positive 50.6% in 2017. Net margin was approximately negative 357.3% in 2018, compared with approximately positive 47.4% in 2017. These percentages are derived from reported revenue and earnings.
Operating cash flow was positive primarily because of $480,649 of non-cash stock-based compensation and favorable changes in operating assets. The company paid $150,000 of related-party debt in January 2018, leaving no related-party notes payable at December 31, 2018. Total liabilities were $39,136, consisting of accounts payable and accrued expenses.
Material Changes Versus the Prior Comparable Period
- Revenue fell sharply after the biotech licensing stream ended, declining from $852,443 to $190,094.
- The company moved from $404,353 of net income in 2017 to a $679,078 net loss in 2018.
- Research and development spending nearly tripled, reflecting increased product development and work related to the Duke/374Water project.
- Stock-based compensation of $480,649 was recognized in 2018, including costs related to the May 2018 repricing and issuance of options.
- Working capital shifted from a $168,859 surplus to a $9,788 deficit, while year-end cash remained only $8,482.
- The $150,000 balance of prior related-party notes was paid in January 2018.
- On May 30, 2018, outstanding management and non-employee options and warrants covering 5,975,000 shares were extended or repriced, generally to a $0.12 exercise price and a June 30, 2026 expiration date. Options outstanding totaled 11,180,500 at year-end.
Guidance, Outlook, Risks and Unusual Items
Management expected a purchase order of approximately $500,000 from 374Water after 374Water completed a private-equity financing, which management believed could occur in the second quarter of 2019. The filing expressly states that the financing, purchase order, and 374Water's business prospects were uncertain. Management also stated that failure to receive the order would materially adversely affect the company because it had no alternative source of material near-term revenue.
The company reported substantial doubt about its ability to continue as a going concern. The auditor highlighted recurring losses, negative operating cash flows, expiration of the principal licensing revenue source, accumulated deficit of $12,057,798, and the need for additional financing. Management stated that failure to raise capital could force the company to cease operations.
In the first quarter of 2019, the company issued $290,000 of Series B convertible promissory notes to stockholders. The notes bear interest at 10%, mature December 31, 2021, and are convertible at prices ranging from $0.20 to $0.40 per share depending on the conversion date.
- The company has not demonstrated commercial-scale or continuous operation of its systems; it cited difficulty achieving the targeted 20,000 hours of continuous operation.
- The company faces significant competition from better-capitalized energy and engineering companies.
- Additional equity or debt financing may dilute existing shareholders or impose repayment obligations; the common stock is thinly traded and subject to penny-stock rules.
- The company relies heavily on a small number of personnel and uses a facility without a signed lease.
- Patent issuance, maintenance, enforceability, and protection of trade secrets remain uncertain.
- A 2% royalty is payable to a consultant on revenue from products or projects based on an assigned patent.
- Under a Helidyne license, potential minimum royalties could apply if the company commercializes relevant technology, although management stated performance by Helidyne was unlikely.
- No cash dividends have been paid or are expected in the foreseeable future.
Most Important Facts for Investors to Verify
- Confirm the registrant's current corporate identity and whether this PowerVerde filing is the correct filing for 374Water Inc.
- Verify whether the anticipated approximately $500,000 374Water purchase order was issued, funded, and recognized as revenue after year-end.
- Review subsequent financing, liquidity, and going-concern disclosures, including the $290,000 Series B convertible notes.
- Confirm whether the company generated any material revenue from its planned power-generation or specialty-engineering operations.
- Assess the sustainability of positive 2018 operating cash flow, given the large non-cash stock-based compensation component and the loss of licensing revenue.
- Evaluate dilution from 11,180,500 outstanding options, 975,000 warrants, and potential conversion of the Series B notes.
- Verify technical milestones, customer commitments, intellectual-property rights, and the ability to achieve commercially reliable continuous operation.